Breaking News

EU Authorities Lift GMP Suspension at Ranbaxy’s Toansa Site

June 5, 2014

Will reinstate GMP certificate

European regulatory authorities have finalized an assessment of reported non-compliance with GMP at Ranbaxy Labs’ manufacturing site in Toansa, India. While the assessment showed a number of GMP deficiencies at the site, European regulators concluded that there has been no risk to public health from these deficiencies. European regulators reviewed the corrective measures put in place by the company and found them to be sufficient to ensure GMP compliance, and, as a result, will reinstate the GMP certificate that was suspended in January 2014.  

The assessment followed an inspection by the FDA, which revealed areas of non-compliance at the site. The European medicines regulatory network responded to the FDA’s findings, sending a team of inspectors from Germany, Ireland and the UK, along with inspectors from Switzerland and Australia to undertake an international inspection of the site.

The inspection team concluded that medicines on the EU market that have an API manufactured in Toansa were of acceptable quality presented no risk to patients. This conclusion was supported by tests of samples of these medicines, all of which met the correct quality specifications.

European regulatory authorities will continue to monitor the Toansa site in collaboration with India and other regulatory authorities.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks